Aldeyra Therapeutics Inc. has announced that Chief Development Officer Stephen G. Machatha, Ph.D., will resign from his position, effective on or before March 31, 2026. Under a new Transition Agreement, Dr. Machatha will continue to receive his current base salary and employee benefits until his departure. He will also be eligible for continued vesting of his outstanding stock options and restricted stock units during this transition period. In addition, Dr. Machatha will receive a lump sum payment of $88,000, representing 50% of his potential 2025 bonus based on 110% of his target bonus, in exchange for executing the Transition Agreement. If he executes an additional release of claims after his separation, he will be entitled to another lump sum payment of $88,000, representing the remaining 50% of his potential 2025 bonus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-338394), on December 31, 2025, and is solely responsible for the information contained therein.